BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Z, Zhang X, Guo Z, Zhong Y, Wang P, Li J, Li Z, Liu P. SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy. Front Pharmacol 2018;9:1519. [PMID: 30670969 DOI: 10.3389/fphar.2018.01519] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Guajardo-correa E, Silva-agüero JF, Calle X, Chiong M, Henríquez M, García-rivas G, Latorre M, Parra V. Estrogen signaling as a bridge between the nucleus and mitochondria in cardiovascular diseases. Front Cell Dev Biol 2022;10:968373. [DOI: 10.3389/fcell.2022.968373] [Reference Citation Analysis]
2 Li Z, Lu G, Lu J, Wang P, Zhang X, Zou Y, Liu P. SZC-6, a small-molecule activator of SIRT3, attenuates cardiac hypertrophy in mice. Acta Pharmacol Sin. [DOI: 10.1038/s41401-022-00966-8] [Reference Citation Analysis]
3 Zhong QH, Zha SW, Lau ATY, Xu YM. Recent knowledge of NFATc4 in oncogenesis and cancer prognosis. Cancer Cell Int 2022;22:212. [PMID: 35698138 DOI: 10.1186/s12935-022-02619-6] [Reference Citation Analysis]
4 Shao Y, Wang X, Zhou Y, Jiang Y, Wu R, Lu C. Pterostilbene attenuates RIPK3-dependent hepatocyte necroptosis in alcoholic liver disease via SIRT2-mediated NFATc4 deacetylation. Toxicology 2021;461:152923. [PMID: 34474091 DOI: 10.1016/j.tox.2021.152923] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Zhang X, Zhang Z, Wang P, Han Y, Liu L, Li J, Chen Y, Liu D, Wang J, Tian X, Zhao Q, Yan F. Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism. Front Pharmacol 2021;12:653901. [PMID: 34149410 DOI: 10.3389/fphar.2021.653901] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Li Z, Guo Z, Lan R, Cai S, Lin Z, Li J, Wang J, Li Z, Liu P. The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy. Acta Pharm Sin B 2021;11:1286-99. [PMID: 34094834 DOI: 10.1016/j.apsb.2020.12.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Palomer X, Aguilar-Recarte D, García R, Nistal JF, Vázquez-Carrera M. Sirtuins: To Be or Not To Be in Diabetic Cardiomyopathy. Trends Mol Med 2021;27:554-71. [PMID: 33839024 DOI: 10.1016/j.molmed.2021.03.004] [Reference Citation Analysis]
8 Li X, Liu L, Li T, Liu M, Wang Y, Ma H, Mu N, Wang H. SIRT6 in Senescence and Aging-Related Cardiovascular Diseases. Front Cell Dev Biol 2021;9:641315. [PMID: 33855020 DOI: 10.3389/fcell.2021.641315] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
9 Liu G, Chen H, Liu H, Zhang W, Zhou J. Emerging roles of SIRT6 in human diseases and its modulators. Med Res Rev 2021;41:1089-137. [PMID: 33325563 DOI: 10.1002/med.21753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang P, Lan R, Guo Z, Cai S, Wang J, Wang Q, Li Z, Li Z, Wang Q, Li J, Wu Z, Lu J, Liu P. Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression. Front Cell Dev Biol 2020;8:548605. [PMID: 33117796 DOI: 10.3389/fcell.2020.548605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Saiyang X, Deng W, Qizhu T. Sirtuin 6: A potential therapeutic target for cardiovascular diseases. Pharmacol Res 2021;163:105214. [PMID: 33007414 DOI: 10.1016/j.phrs.2020.105214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
12 Lei H, Hu J, Sun K, Xu D. The role and molecular mechanism of epigenetics in cardiac hypertrophy. Heart Fail Rev 2020. [PMID: 32297065 DOI: 10.1007/s10741-020-09959-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]